National Resilience – a technology-focused biomanufacturing company dedicated to broadening access to complex medicines – announced that its subsidiary Resilience Government Services has been awarded nearly $17.5 million in new funding from the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) – part of the U.S. Department of Health and Human Services to support the domestic production of key starting materials and active pharmaceutical ingredients for essential medicines.
This funding is a result of a project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), which is a public-private partnership established in January 2024 to help expand the domestic industrial and biomanufacturing base for medical countermeasures by leveraging the capabilities of industry partners across the drug manufacturing supply chain.
As part of the agreement, Resilience has partnered with Aralez Bio, a biotechnology company creating next-generation amino acids through an advanced proprietary platform technology harnessing the power of biocatalysis.
As part of this agreement, Resilience will leverage its current Good Manufacturing Process (cGMP) manufacturing infrastructure, analytical development expertise, and regulatory and quality experience to fortify the pharmaceutical supply chain and enhance the production of the nation’s critical medicines. This project was funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Office of Industrial Base Management and Supply Chain (IBMSC), under OT number #75A50123D00003.
This effort helps ensure the availability of life-saving medicines currently in drug shortage and supports the BioMaP-Consortium’s mission and commitment to addressing critical gaps in pharmaceutical manufacturing through public-private partnerships. And the funding will enable cGMP manufacturing using Aralez Bio’s cutting-edge technology platform to streamline production processes for active pharmaceutical ingredients made within the United States, including submitting the necessary data to the U. S. Food and Drug Administration for Resilience to become an approved domestic Active Pharmaceutical Ingredient (API) supplier for pharmaceutical manufacturers.
KEY QUOTES:
“Securing this manufacturing program for Resilience is a good step forward for the U.S. pharmaceutical manufacturing industry to ensure a more resilient and responsive supply chain. With the support from both public and private sectors, we are positioned to enhance and expand domestic production of key starting materials and active pharmaceutical ingredients that often fall into short supply.”
-Rahul Singhvi, ScD., Chief Executive Officer at Resilience
“Aralez Bio’s proprietary enzyme platform is at the forefront of amino acid chemistry. When combined with Resilience’s groundbreaking approach to revolutionizing pharmaceutical manufacturing, this collaboration is strengthening the security of our supply chains. We are excited to partner with Resilience and contribute to the renewal of the domestic bioeconomy.” This announcement represents the dedication of private and public industry leaders to delivering essential pharmaceutical ingredients to meet domestic healthcare needs.”
-Tina Boville, PhD, Chief Executive Officer of Aralez Bio
